Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check5 days agoChange DetectedThe page’s revision/version indicator has been updated from v3.5.2 to v3.5.3, reflecting a general site release without altering the underlying study information.SummaryDifference0.0%

- Check12 days agoChange DetectedRegional names Královéhradecký kraj and Olomoucký kraj were updated to Hradec Králové Region and Olomouc Region, respectively, with the corresponding addresses adjusted. The revision tag was updated to v3.5.2.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAdded Padova, Italy, 35128 and removed Padua, Italy, 35128 from the locations list.SummaryDifference0.0%

- Check33 days agoChange DetectedNapoli, Italy, 80131 was replaced with Naples, Italy, 80131 in the locations section.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision label updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.